Enanta Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENTA research report →
Companywww.enanta.com
Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.
- CEO
- Jay R. Luly
- IPO
- 2013
- Employees
- 131
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $319.96M
- P/E
- -6.42
- P/S
- 4.62
- P/B
- 3.42
- EV/EBITDA
- -9.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.25%
- Op Margin
- -87.24%
- Net Margin
- -89.56%
- ROE
- -64.04%
- ROIC
- -19.90%
Growth & Income
- Revenue
- $65.32M · -3.42%
- Net Income
- $-81,889,000 · 29.43%
- EPS
- $-3.84 · 29.93%
- Op Income
- $-85,349,000
- FCF YoY
- 66.74%
Performance & Tape
- 52W High
- $17.15
- 52W Low
- $5.55
- 50D MA
- $13.62
- 200D MA
- $12.23
- Beta
- 1.01
- Avg Volume
- 166.39K
Get TickerSpark's AI analysis on ENTA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 26 | Vance Terry | other | 20,000 |
| Mar 11, 26 | Russell Lesley | other | 20,000 |
| Mar 11, 26 | Peterson Kristine | other | 20,000 |
| Mar 11, 26 | Hata Yujiro S | other | 20,000 |
| Mar 11, 26 | FOLETTA MARK G | other | 20,000 |
| Mar 11, 26 | CARTER BRUCE L A | other | 20,000 |
| Feb 12, 26 | Kowalsky Matthew Paul | other | 4,175 |
| Feb 12, 26 | Kowalsky Matthew Paul | other | 1,902 |
| Feb 12, 26 | Kowalsky Matthew Paul | other | 1,318 |
| Feb 12, 26 | Luu Brendan | other | 4,987 |
Our ENTA Coverage
We haven't published any research on ENTA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENTA Report →